NCT04663997
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- NCT04663997 ↗
- Active, not recruiting
- Canadian Cancer Trials Group
- Deep
We haven't built an HCP commentary report on NCT04663997 (177Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 40 newest of 45 indexed sources (Jun 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether docetaxel or lutetium PSMA should come first
- How to interpret overall survival alongside radiographic progression-free survival
- How crossover affects interpretation of overall survival
- Which patient features should guide treatment selection
Also discussed: patient-reported quality of life.
Indexed commentary on NCT04663997 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 25 | |
| Podcasts | 11 | |
| YouTube | 9 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- 177Lu-PSMA-617; Docetaxel
- Arms
- 177 Lu-PSMA-617 · Experimental
- Docetaxel · Active comparator
- Enrollment
- 200
- Primary outcomes
- Progression-free survival
- Sponsor
- Canadian Cancer Trials Group with Prostate Cancer Canada, Novartis Pharmaceuticals
- Start
- Aug 11, 2021
- Primary completion
- Aug 25, 2025
- Results posted
- No
- Registry record
- NCT04663997 · updated Mar 27, 2026